TVGN - NASDAQ
Tevogen Bio Holdings Inc.
$0.25
-5.8%Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
At a Glance
Live SnapshotTevogen Bio Holdings Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Tevogen Bio Holdings Inc. Cash Flow Statement
TVGN • NASDAQ
| Tevogen Bio Holdings Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-13.7M | -60.5M | -22M | -15.6M | |
403.6K | 378.4K | 230.8K | 9.4K | |
40.8M | 0.0 | 4.6M | 582.4K | |
-39.4M | 51.6M | 8.7M | 11M | |
-5.5K | 293.2K | -96.9K | -1.2M | |
-12M | -8.2M | -8.7M | -5.3M | |
INVESTING ACTIVITIES | ||||
(0.0) | -133K | -479K | -109.7K | |
(0.0) | -133K | -479K | -109.7K | |
FINANCING ACTIVITIES | ||||
0.0 | -343M | 0.0 | 0.0 | |
1M | 4M | 7.5M | 12.5M | |
(0.0) | -343M | (0.0) | (0.0) | |
229.3K | 342.9M | 0.0 | 0.0 | |
12.2M | 3.9M | 7.5M | 12.5M | |
CASH FLOW SUMMARY | ||||
230.6K | -4.4M | -1.6M | 7.1M | |
1.1M | 5.5M | 7.1M | 3.8K | |
1.3M | 1.1M | 5.5M | 7.1M | |
-12M | -8.3M | -9.1M | -5.4M |
SEC Filings
TVGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | February 25, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 26, 2026 | January 26, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 26, 2025 | September 23, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 14, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 10, 2025 | July 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 03, 2025 | July 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 30, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 23, 2025 | June 23, 2025 | 2025 |
Related Guides
Continue your TVGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.